These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 35858584)
1. Gitelman's and Bartter's Syndromes: From Genetics to the Molecular Basis of Hypertension and More. Ravarotto V; Bertoldi G; Stefanelli LF; Nalesso F; Calò LA Kidney Blood Press Res; 2022; 47(9):556-564. PubMed ID: 35858584 [TBL] [Abstract][Full Text] [Related]
2. Are the Clinical Presentations (Phenotypes) of Gitelman's and Bartter's Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their "pH" Enotype? Calò LA; Davis PA Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784543 [TBL] [Abstract][Full Text] [Related]
3. Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartter's and Gitelman's syndromes. Calò LA; Maiolino G J Endocrinol Invest; 2015 Jul; 38(7):711-6. PubMed ID: 25740064 [TBL] [Abstract][Full Text] [Related]
4. Molecular pathophysiology of Bartter's and Gitelman's syndromes. Koulouridis E; Koulouridis I World J Pediatr; 2015 May; 11(2):113-25. PubMed ID: 25754753 [TBL] [Abstract][Full Text] [Related]
5. Paradoxes in magnesium transport in type 1 Bartter's syndrome and Gitelman's syndrome: a modeling analysis. Dutta P; Layton AT Am J Physiol Renal Physiol; 2024 Sep; 327(3):F386-F396. PubMed ID: 38991009 [TBL] [Abstract][Full Text] [Related]
6. High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes): are angiotensin II type 2 receptors involved? Calò LA; Montisci R; Scognamiglio R; Davis PA; Pagnin E; Schiavo S; Mormino P; Semplicini A; Palatini P; D'Angelo A; Pessina AC J Endocrinol Invest; 2009 Nov; 32(10):832-6. PubMed ID: 19605975 [TBL] [Abstract][Full Text] [Related]
7. Miscellaneous non-inflammatory musculoskeletal conditions. Bartter's and Gitelman's diseases. Favero M; Calò LA; Schiavon F; Punzi L Best Pract Res Clin Rheumatol; 2011 Oct; 25(5):637-48. PubMed ID: 22142744 [TBL] [Abstract][Full Text] [Related]
8. Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter's and Gitelman's syndromes, human models of endogenous angiotensin II signaling antagonism. Calò LA; Davis PA; Rossi GP J Hypertens; 2014 Nov; 32(11):2109-19; discussion 2119. PubMed ID: 25202962 [TBL] [Abstract][Full Text] [Related]
9. Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients. Calò LA; Davis PA; Pagnin E; Dal Maso L; Maiolino G; Seccia TM; Pessina AC; Rossi GP J Hypertens; 2014 Feb; 32(2):331-8. PubMed ID: 24356540 [TBL] [Abstract][Full Text] [Related]
10. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. Calò LA; Puato M; Schiavo S; Zanardo M; Tirrito C; Pagnin E; Balbi G; Davis PA; Palatini P; Pauletto P Nephrol Dial Transplant; 2008 Sep; 23(9):2804-9. PubMed ID: 18344243 [TBL] [Abstract][Full Text] [Related]
11. Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension. Ravarotto V; Pagnin E; Fragasso A; Maiolino G; Calò LA High Blood Press Cardiovasc Prev; 2015 Sep; 22(3):215-23. PubMed ID: 25759028 [TBL] [Abstract][Full Text] [Related]
12. Oxidants and Cardiorenal Vascular Remodeling-Insights from Rare Genetic Tubulopathies: Bartter's and Gitelman's Syndromes. Sgarabotto L; Ravarotto V; Stefanelli LF; Cacciapuoti M; Davis PA; Nalesso F; Calò LA Antioxidants (Basel); 2023 Mar; 12(4):. PubMed ID: 37107186 [TBL] [Abstract][Full Text] [Related]
13. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. Calò LA; Pagnin E; Ceolotto G; Davis PA; Schiavo S; Papparella I; Semplicini A; Pessina AC J Hypertens; 2008 May; 26(5):938-45. PubMed ID: 18398336 [TBL] [Abstract][Full Text] [Related]
14. Reduced mRNA and protein content of rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes: relevance for the pathophysiology of hypertension. Pagnin E; Semplicini A; Sartori M; Pessina AC; Calò LA Am J Hypertens; 2005 Sep; 18(9 Pt 1):1200-5. PubMed ID: 16182110 [TBL] [Abstract][Full Text] [Related]
15. ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes. Calò LA; Rigato M; Sgarabotto L; Gianesello L; Bertoldi G; Ravarotto V; Davis PA Front Med (Lausanne); 2021; 8():647319. PubMed ID: 34017843 [TBL] [Abstract][Full Text] [Related]
16. The Dietary Approach to the Treatment of the Rare Genetic Tubulopathies Gitelman's and Bartter's Syndromes. Francini F; Gobbi L; Ravarotto V; Toniazzo S; Nalesso F; Spinella P; Calò LA Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578838 [TBL] [Abstract][Full Text] [Related]
17. Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling. Pagnin E; Davis PA; Sartori M; Semplicini A; Pessina AC; Calò LA J Hypertens; 2004 Oct; 22(10):1963-9. PubMed ID: 15361768 [TBL] [Abstract][Full Text] [Related]
19. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. Calò LA; Schiavo S; Davis PA; Pagnin E; Mormino P; D'Angelo A; Pessina AC J Hypertens; 2010 Jan; 28(1):111-8. PubMed ID: 19797979 [TBL] [Abstract][Full Text] [Related]
20. Oxidative stress-related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Calò LA; Pagnin E; Davis PA; Sartori M; Semplicini A Nephrol Dial Transplant; 2003 Aug; 18(8):1518-25. PubMed ID: 12897089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]